Register for free to
view the full innovation profile.
Naturally occurring protein well documented as being involved in endogenous multi-modal reparative processes associated with neurodegenerative and other indications.
About
University of Tasmania researchers have developed a novel therapeutic composition based on Metallothionein (MT). MT is a naturally occurring protein well documented as being involved in endogenous multi-modal reparative processes associated with neurodegenerative and other indications. MT has an excellent toxicology profile. The University of Tasmania has protected therapeutic applications of MT. Value Proposition Under a separate patent, the University of Tasmania has protected peptide analogues of MT. The patent protection applies across any therapeutic applications of MT, (the subject of this patent) providing a strong intellectual property position for the development of any derivatives or synthetic analogues of MT. The value proposition is access to a defensive patent position around a wide range therapeutic applications of Metallothionein.